Welcome to our dedicated page for Fibrobiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on Fibrobiologics stock.
FibroBiologics, Inc. (Nasdaq: FBLG) is a clinical-stage biotechnology company based in Houston that focuses on developing fibroblast-based therapies and fibroblast-derived materials for chronic diseases. News about FibroBiologics often centers on progress in its pipeline, intellectual property developments, and financing activities that support its research and clinical plans.
Company updates include announcements on preclinical and clinical milestones, such as HREC approval in Australia for a Phase 1/2 trial of CYWC628 in diabetic foot ulcers and the filing of a Phase 1/2 IND application with the U.S. FDA for CYPS317 in moderate to severe psoriasis. FibroBiologics also reports preclinical data for programs like CYMS101 for multiple sclerosis and FSdC spheroid therapies for degenerative disc disease, as well as work in bone marrow organoids for cancer and human longevity applications.
Investors following FBLG news will also see coverage of patent filings and intellectual property expansions, including a U.S. patent application for fibroblast-derived spheroids for cartilage and joint repair, and disclosures about the company’s portfolio of more than 270 issued and pending patents. Capital markets news features registered direct offerings, concurrent private placement warrants, and the use of a Standby Equity Purchase Agreement, along with updates on the payoff of outstanding convertible debt.
This news feed aggregates these types of developments in one place, from clinical and scientific updates to proxy statements, Nasdaq compliance notices, and financing transactions. Readers can use it to monitor FibroBiologics’ progress across its fibroblast-based platforms and to track regulatory, corporate, and capital markets events that may affect the FBLG stock.
FibroBiologics (NASDAQ: FBLG) closed a best-efforts public offering on April 2, 2026, selling 2,272,728 shares and warrants to purchase up to 2,272,728 shares at a combined public offering price of $1.32 per share and warrant.
The offering generated approximately $3 million gross proceeds before fees; the Warrants carry a $1.32 exercise price and, if fully exercised, could provide an additional ~$3 million. Warrants become exercisable upon stockholder approval and expire five years after that date.
FibroBiologics (NASDAQ: FBLG) priced a best-efforts public offering of 2,272,728 common shares and warrants at a combined price of $1.32 each, expected to raise approximately $3.0 million gross, before fees. Warrants cover up to 2,272,728 shares at a $1.32 exercise price.
The offering closing is expected on or about April 2, 2026, subject to customary conditions and stockholder approval for warrant exercises; potential additional gross proceeds from full warrant exercise equal approximately $3.0 million. Net proceeds are for working capital and general corporate purposes.
FibroBiologics (Nasdaq: FBLG) announced completion of manufacturing the first batch of its proprietary CYWC628 drug product to support planned first‑in‑human trials.
The product was manufactured under FDA CGMP standards and will be released after required safety and quality testing. The company plans a Phase 1/2 diabetic foot ulcer trial in the first half of 2026.
FibroBiologics (Nasdaq: FBLG) announced a 1-for-20 reverse stock split expected to take effect at 12:01 a.m. ET on March 30, 2026, to regain compliance with Nasdaq's minimum bid price requirement.
Post-split outstanding shares will decrease from 70,256,883 to approximately 3,512,845, fractional shares rounded up, and trading will continue under the ticker FBLG.
FibroBiologics (Nasdaq: FBLG) announced expansion of its wound care platform into acute and chronic burn treatment using its proprietary fibroblast spheroid therapy CYWC628.
In preclinical burn models, CYWC628 increased tissue IL-10 nearly four-fold and reduced IL-1B, suggesting faster, higher-quality healing; company plans to advance toward clinical development and integrate burn work into its wound care strategy.
The release cites a global burn care market of $2.55B today, growing to $3.35B by 2030.
FibroBiologics (Nasdaq: FBLG) completed onboarding of clinical sites for its Phase 1/2 trial of CYWC628, an allogeneic fibroblast spheroid topical therapy for refractory diabetic foot ulcers.
The prospective, multicenter, open-label study will test low and high doses plus standard of care for up to 12 weeks, with an interim analysis after a predefined cohort completes six weeks. Southern Star Research will manage trial operations across APAC.
FibroBiologics (Nasdaq: FBLG) announced issuance of U.S. Patent No. 12,544,407 B2, dated February 10, 2026, covering fibroblast cell therapy for osteoporosis. The patent claims systemic and local administration, modified/dedifferentiated fibroblasts (OCT4, NANOG, SOX2), recombinant CXCR4/hTERT, marker-selected cells, and combination use with anti-inflammatory agents.
This issuance strengthens the company’s intellectual property in regenerative medicine and bone disorders and supports its strategy to develop proprietary fibroblast therapies addressing osteoporosis and related bone diseases.
FibroBiologics (Nasdaq: FBLG) announced its Founder and CEO, Pete O’Heeron, will present at the BIO Investment & Growth Summit March 2-3, 2026, at Eden Roc, Miami Beach. The company presentation is scheduled for 10:15 a.m. ET on Monday, March 2, and management will hold one-on-one meetings during the event.
Investors can obtain more information via the company website or by contacting info@fibrobiologics.com; social channels include LinkedIn, YouTube, Facebook and X.
FibroBiologics (Nasdaq: FBLG) reported full-year 2025 results and a corporate update on Feb 24, 2026. Key items: HREC approvals in Australia for a Phase 1/2 CYWC628 diabetic foot ulcer trial enrolling 120 patients; IND filed for CYPS317 in psoriasis; raised $7.2M and repaid all debt. Financials: R&D $7.4M, G&A $9.2M, net loss $18.6M, cash $4.9M. Upcoming: dose first patient and interim DFU results in H1 2026; IND milestones for psoriasis and MS in H1 2026.
FibroBiologics (Nasdaq: FBLG) received a Nasdaq Hearings Panel extension to regain compliance and maintain its Nasdaq Capital Market listing. The company must meet the $2.5 million equity standard by Feb 27, 2026, achieve a minimum bid price of $1.00 by Apr 13, 2026, and satisfy all continued-listing criteria by Apr 13, 2026. Trading of FBLG shares continues uninterrupted.